Los Angeles vs Houston: Oncology, Medical Research, Life Sciences & Pharma
A multi-source, adversarially fact-checked comparison of senior compensation across two of the country's biggest medical economies. Every headline figure below survived a 3-vote verification pass; the numbers that didn't are listed openly in Chapter 09.
Executive summary #
For senior, 10-plus-year roles, Los Angeles pays a higher nominal salary than Houston across nearly every segment — but Houston wins decisively on real, cost-of-living-and-tax-adjusted take-home. That is the entire story in one sentence, and it holds from the bench technician to the cancer-center CEO.
The one exception, and it is a large one, sits at the top of the industry ladder. LA has a deep, equity-rich commercial biotech cluster (Amgen, Kite/Gilead) that pays its executives $8M–$24M+ with most of it in stock. Houston has no local comparator. So LA's ceiling for industry leadership is far higher — not because of base salary, but because of equity that Houston's economy simply doesn't generate.
The verified headline numbers
| Segment (senior / 10+ yr) | Los Angeles | Houston | Confidence |
|---|---|---|---|
| All-physician metro average | $470,198 | $422,458 | High |
| Oncology subspecialties (national avg)* | Med-onc ~$502K · Rad-onc ~$589K · Heme ~$421K | High | |
| Medical scientists (PhD), mean | $123,010 | not separately verified | Mixed |
| Natural-sciences managers (R&D dir.), mean | $188,240 | not separately verified | High (LA) |
| Lab / technical (tech & biological), mean | $58K–$69K | lower (general market) | High (LA) |
| Industry medical-affairs director (national) | Director MSL ~$219K vs IC ~$179K (~22% title premium) | Medium | |
| Large-org executive ceiling | $8M–$24M+ (equity) | ~$3M–$8M (no equity) | High |
*Oncology figures are national specialty averages. A verified LA-vs-Houston split specific to oncology subspecialties does not exist in the available sources — see Chapter 09.
Every LA advantage in this report is pre-adjustment (nominal). Apply cost of living and tax (Chapter 02) and most of them flip to Houston. And do not double-count tax: the purchasing-power figures are already net of income tax, so you can't layer a separate CA tax penalty on top of them.
The central tension: nominal vs real #
Any honest LA-vs-Houston pay comparison has to answer two different questions, because they give opposite answers.
Question 1 — what's the number on the offer letter? Los Angeles, almost always. It is a higher-cost, higher-wage coastal market with a denser life-science economy, and employers price salaries to that reality.
Question 2 — what does that number actually buy you? Houston, almost always. Lower-cost housing and no state income tax mean a smaller Houston salary frequently delivers more real purchasing power than a larger LA one.
This is not a rounding-error effect. The cost-of-living gap (Houston ~33.6% cheaper overall) is large enough that a Houston role paying 15–25% less in gross dollars can leave the worker with more money after housing and taxes. For senior roles — where housing is a smaller share of a big budget but state tax is a bigger one — Texas's zero income tax does a lot of the work.
The nominal-vs-real frame governs salary. It does not govern equity. When LA's biotech executives earn millions in Amgen or Gilead stock, no amount of Houston cost-of-living advantage closes that gap — because Houston doesn't offer the role at all. See Chapter 05 and Chapter 07.
Cost of living & the tax equalizer #
This is the single most important chapter, because it reverses the headline. All figures below were verified 3-0.
| Factor | LA vs Houston | Source |
|---|---|---|
| Overall cost of living | Houston 33.6% cheaper | Salary.com |
| Cost incl. rent | LA 43.4% higher | Numbeo |
| Cost excl. rent | LA 30.9% higher | Numbeo |
| Rent (the dominant driver) | LA 67.6% higher | Numbeo (corroborated ~65% by usrentprices) |
| Local purchasing power | LA 33.3% lower | Numbeo (net of tax) |
| State income tax | CA up to 13.3% vs TX 0% | State tax codes |
How the tax gap scales with seniority
State income tax is the lever that matters most for the 10-plus-year, high-earner population this report targets. California's top marginal rate reaches 13.3% (with a 1% mental-health surcharge above $1M of income); Texas levies nothing. On a $400,000 senior-physician salary, the CA state tax bite is on the order of $30,000–$40,000 per year that a Houston peer simply keeps. On a $2M executive cash package it is $250,000+ per year. That gap compounds every single year of a tenured career.
Numbeo's "local purchasing power" index is already net of income tax. If you start from that 33.3% figure and then also subtract CA income tax, you are penalizing California twice. Use either the purchasing-power index or a from-scratch gross-to-net model — never both stacked.
A cleaner way to think about it: to match a given Houston net lifestyle, an LA gross salary needs to be roughly 15–25% higher — and more than that once the housing premium is fully loaded. LA's ~11% nominal physician premium does not clear that bar. Houston wins on real comp.
The cost-of-living figures lean on crowdsourced Numbeo and Salary.com calculators — directionally reliable but snapshot-dependent and volatile. The authoritative BEA Regional Price Parities would be the gold standard and were not retrieved in this pass. Treat "Houston ~one-third cheaper, driven mostly by housing" as the robust claim; treat the exact percentages as approximate.
Clinical oncology physicians #
This is the highest-paid segment, and the one where the data is strongest at the metro level but weakest at the subspecialty level.
What is verified (3-0)
Doximity's 2025 Physician Compensation Report (37,000+ surveys collected in 2024) puts the all-physician average at $470,198 in Los Angeles vs $422,458 in Houston — a $47,740 (~11%) nominal LA premium. LA ranks 3rd among all U.S. metros and is the highest-paying California metro listed (ahead of San Jose, Sacramento, Riverside, and San Francisco). National oncology-subspecialty averages anchor the high end:
| Oncology subspecialty | National average (Doximity 2025) |
|---|---|
| Radiation oncology | $588,678 |
| Medical oncology | $502,465 |
| Hematology | $421,482 |
| (All-physician national avg) | $429,808 |
A verified LA-vs-Houston split specific to oncology subspecialties does not exist in the available sources. The cleanest-looking such figures — SalaryDr's "$380K LA vs $340K Houston" hematology/oncology, and Marit Health's Texas academic-vs-private splits — were refuted 0-3 in verification (thin self-reported samples). So combine the two verified facts: a ~11% all-physician LA metro premium, layered on national oncology averages. Don't treat any tidy oncology-specific metro dollar gap as fact.
The Houston counterweight
Houston is home to MD Anderson, consistently ranked the #1 cancer hospital in the U.S., inside the Texas Medical Center — the world's largest medical complex. For an oncologist, Houston offers top-tier institutional prestige, high case volume, no state income tax, and roughly half the housing cost of LA. The nominal pay is ~11% lower; the real, after-tax, after-housing position generally favors Houston.
Academic & institutional research scientists #
PhD bench/translational scientists, principal investigators, biostatisticians. The reliable anchor here is BLS occupational wage data for the LA metro.
| Role (LA-Long Beach-Anaheim) | Annual mean | Employed | SOC |
|---|---|---|---|
| Medical Scientists (exc. epidemiologists) | $123,010 | 6,490 | 19-1042 |
| Natural Sciences Managers (R&D directors) | $188,240 | 2,230 | 11-9121 |
BLS OEWS, May 2023 (current release at research time), verified verbatim via archive. These broad SOC categories are proxies — they are not tenure-specific, so a 10-plus-year senior PI sits in the upper portion of these distributions, not at the mean.
The Houston academic anchor
For Houston academic medicine, Baylor College of Medicine full Professors averaged $235,314 reported faculty salary (2024-25, n=102, IPEDS-derived, 9-month-equated). Important caveat: that figure excludes practice-plan and clinical compensation, so it materially understates true physician-faculty total pay. A narrower claim about Baylor Associate/Assistant professor figures was refuted 0-3 and is excluded.
Houston-metro BLS wages for the same SOC codes were not separately captured in the verified claim set, so a clean segment-by-segment academic differential could not be computed from primary data this pass. The robust directional finding holds: Houston is a documented lower-wage market generally, but its real-comp position is buoyed by the same cost/tax advantages as every other segment.
Industry pharma & biotech professionals #
Clinical development, regulatory affairs, medical affairs / MSLs, R&D directors. This is where the two metros diverge most — not on base salary, but on the existence of an equity-rich career track at all.
The verified title premium (national)
A PharmaPayWatch analysis of 910 MSL postings (33 companies, Feb–Aug 2025) found IC medical-affairs median $179,000 vs director/supervisory median $219,000 — a ~22% management premium, corroborated by the MSL Society 2025 survey (MSL ~$176K → Senior MSL ~$195K → Manager ~$209K → Director ~$232K → VP ~$324K). These are national job-posting midpoints excluding bonus and equity, not metro-specific realized comp.
State-specific Senior MSL figures from Salary.com (CA vs TX) were refuted (1-2 votes) and excluded. A clean LA-vs-Houston industry base-salary differential is therefore not firmly established in the sources. What's solid is the title premium and the structural cluster difference below.
The structural divide that matters more than base salary
Public-company executive pay is disclosed in SEC proxy filings, and it tells the real story:
- Los Angeles / SoCal — deep and equity-rich. Amgen (Thousand Oaks) and Kite Pharma / Gilead (Kite's oncology cell-therapy engine is HQ'd in Santa Monica / El Segundo) anchor a market with hundreds of clinical-stage and commercial biotechs, plus adjacency to San Diego and the Bay Area. Senior R&D / clinical-development / regulatory leaders here carry large equity components. A sub-executive VP Clinical Development or VP Regulatory typically runs ~$700K–$2M+ total comp with meaningful equity.
- Houston — thin commercial base. No Amgen/Gilead-scale public pharma HQ. Industry strength is academic/translational (MD Anderson's drug discovery, the emerging TMC3/Helix Park district), not a roster of equity-disclosing public companies. The equity-upside industry track is largely absent inside the metro. A Houston "Head of R&D / CMO" usually means either an early-stage company (lower cash, illiquid private equity) or a relocation.
The absence of a Houston industry comparator isn't a data gap — it is the result. For an industry professional whose comp is driven by stock, LA offers a wealth-creation path that Houston's local economy does not. For one whose comp is base + bonus, the nominal-vs-real logic from Chapter 02 applies and Houston competes well. See Chapter 07 for the top of this ladder.
Life-sciences lab & technical roles #
Lab managers, senior research associates, QA/QC, process/manufacturing technicians. Verified BLS OEWS May 2023 LA-metro means:
| Role (LA metro) | Annual mean | Employed | SOC |
|---|---|---|---|
| Clinical Lab Technologists & Technicians | $68,740 | 10,080 | 29-2010 |
| Biological Technicians | $67,670 | — | 19-4021 |
| Chemical Technicians | $57,870 | — | 19-4031 |
| Lab Managers / R&D Directors (mapped) | $188,240 | 2,230 | 11-9121 |
The senior end of this segment — a lab manager or R&D director with 10+ years — maps to the Natural Sciences Managers band (~$188K), an order of magnitude above the bench-technician tier. Houston-metro equivalents weren't separately captured in the verified set, but Houston is a documented lower-wage market across these occupations (per CBRE, Chapter 08). With cost of living a third lower and no state tax, the real-comp picture for technical staff tracks the same Houston-net-advantage pattern as every other segment, just with smaller absolute dollars where housing is the largest share of a tighter budget.
Executives running large organizations #
The top of the ladder — cancer-center directors, department chairs, health-system C-suites, and pharma/biotech VPs and CXOs. These are the most transparent roles in the whole report, because nonprofit comp is disclosed on IRS Form 990, public-university pay is in state databases, and public-company executive pay is in SEC proxy statements.
Academic & health-system leadership (990 / public-salary disclosed)
| Role / person | Organization | Total comp | Confidence |
|---|---|---|---|
| Los Angeles | |||
| President & CEO (R. Stone) | City of Hope | $6.15M | High |
| President & CEO emeritus (T. Priselac) | Cedars-Sinai Health System | $8.81M | High |
| President UCLA Health (J. Spisso) | UCLA (UC) | ~$2.0M–$2.8M | High |
| Clinical-trials system director (E. Kim) | City of Hope | $1.73M | High |
| Clinical department chairs | UCLA / USC | $1.0M–$1.5M+ | Medium |
| Cancer-center director (recruiting range) | USC Norris | ~$0.85M–$0.95M | Low |
| Houston | |||
| President (P. Pisters) | UT MD Anderson | ~$5.6M (2023) | Med-High |
| President/CEO & Exec Dean (P. Klotman) | Baylor College of Medicine | $2.91M | High |
| President & CEO (M. Boom) | Houston Methodist | high single-digit $M | Medium |
| Department chairs / division heads | MD Anderson | $0.6M–$1.6M | Medium |
The Texas Tribune salary database shows MD Anderson's president at only ~$66K under "general revenue" — because almost none of MD Anderson's pay comes from state general funds. The real ~$5.6M total comes from the institution's own funds and is read off the UT compensation report. Use the institutional total, never the general-revenue line.
Industry executives (SEC DEF 14A — where LA pulls away)
| Role / person | Company (LA metro) | Total comp (FY24 unless noted) |
|---|---|---|
| Chairman & CEO (R. Bradway) | Amgen (Thousand Oaks) | $24.4M |
| EVP & CTO / ex-EVP R&D (D. Reese) | Amgen | $8.13M |
| EVP Commercial (M. Gordon) | Amgen | ~$8.5M |
| Chairman & CEO (D. O'Day) | Gilead / Kite | $23.7M ($28.4M FY25) |
| EVP & CMO (M. Parsey, departed) | Gilead / Kite | $8.1M + $3.4M severance |
| CMO (D. Berger, joined 2025) | Gilead / Kite | $13.9M (FY25, incl. $3M sign-on) |
All from SEC DEF 14A proxies, cross-checked against FiercePharma. Houston has no local comparator to this tier — the equity-rich industry C-suite does not exist in the metro.
At the academic/clinical top, the two metros are genuinely comparable in gross ($5–9M nonprofit CEOs, $1M+ chairs in both), and Houston keeps more of it (no tax, cheaper housing). But LA's ceiling is far higher because of the industry equity track. Houston wins "best lifestyle-adjusted academic/clinical seat"; LA wins "highest absolute ceiling and equity wealth creation."
Cluster strength & demand #
Pay differences trace back to the shape of each metro's life-science economy. Verified from CBRE's 2025 life-sciences talent analysis and Biocom:
| Dimension | Los Angeles – Orange County | Houston |
|---|---|---|
| R&D talent rank (CBRE) | #5 (score 119.7) | #10 (108.3) — biggest riser, +3 spots |
| Medtech rank | #2 (146.3) | — |
| Manufacturing rank | #5 (106.2) | #3 (107.0) — ahead of LA |
| Scale (Greater LA) | 94,585 direct jobs, $60.2B output | fast-rising, smaller commercial base |
| PhD concentration | deep | ~18.5%, strong wage-to-cost ratio |
LA is the deeper, denser R&D and medtech market with greater absolute scale — that depth, plus a liquid executive labor market where people move between academia and equity-paying industry, pulls pay up, especially in R&D. Houston is a faster-rising manufacturing hub (it actually outranks LA there) with a high-quality PhD pool and a strong wage-to-cost ratio — CBRE explicitly notes Houston's lower nominal wages make it more affordable for R&D talent. Greater demand and pay pressure favor LA in research, Houston in manufacturing.
The "LA is substantially deeper" framing earned only a 2-1 verification vote — Houston's PhD-quality pool is genuinely strong, so the gap in talent quality is narrower than the gap in scale. LA leads clearly on absolute size and R&D depth; it does not dominate on every axis.
What we could not verify #
A report is only as trustworthy as the claims it's willing to throw out. The verification pass killed 7 of 25 tested claims (needed 2 of 3 adversarial votes to refute). These are excluded from the findings above and listed here so you know exactly what is not supported:
| Refuted claim | Vote | Why it failed |
|---|---|---|
| SalaryDr: hem/onc $380K LA vs $340K Houston | 0-3 | Thin self-reported sample; not corroborated |
| Marit Health: TX hem-onc avg $537,072 | 0-3 | 11–12 anonymized self-reports; unreliable |
| Marit: TX academic $382,980 vs non-academic $617,200 | 0-3 | Same weak underlying sample |
| Baylor Assoc/Asst prof $131,793 / $98,481 | 0-3 | Could not be corroborated; excluded |
| Salary.com: Senior MSL California $115,312 | 1-2 | State calculator figure not supported |
| Salary.com: Senior MSL Texas $101,972 | 1-2 | Same; no clean CA-vs-TX MSL split stands |
| Amgen declined $550M Houston facility over workforce | 1-2 | Single weak source; refuted |
Open questions a deeper pass would answer
- Metro-specific (LA vs Houston) base and total comp for individual oncology subspecialties at 10+ years — distinct from the all-physician metro average and national specialty averages.
- Houston-metro BLS OEWS wages for the same SOC codes used in LA, to compute a direct academic/technical differential.
- Authoritative BEA Regional Price Parities (to replace crowdsourced Numbeo/Salary.com) and a full after-tax, after-housing net-comp model per segment.
- Total-comp components (equity, bonus, RVU/productivity, practice-plan income) by metro — base-only figures understate realized pay most for physicians and biotech directors.
Method & sources #
This report fused two research streams. A deep-research harness fanned out across 6 search angles, fetched 28 sources, extracted 88 claims, and adversarially verified the top 25 (3 independent skeptic votes each; a claim needed 2 of 3 refutes to be killed) — 18 confirmed, 7 killed. A parallel executive-compensation pass mined primary disclosure filings (IRS 990s, SEC proxies, public-university salary databases).
Source quality tiers
- Strong / primary: Doximity 2025 (physician comp); BLS OEWS (occupational wages); CBRE & Biocom (cluster); IRS Form 990 via ProPublica Nonprofit Explorer; SEC DEF 14A proxies; UC/Texas public salary databases.
- Indicative / weaker: Numbeo and Salary.com cost-of-living calculators (crowdsourced, volatile); recruiting-listing salary ranges; structural inferences for sub-disclosure-threshold roles.
- Excluded: the 7 refuted claims in Chapter 09.
Vintage
BLS data is May 2023 (current release at research time). Doximity, CBRE, and Biocom reflect 2024 data. Nonprofit 990s and SEC proxies are FY2022–FY2025 depending on the filer. Baylor faculty salary is IPEDS 9-month-equated and understates clinical-faculty total comp.
Key source links
- Doximity 2025 Physician Compensation Report
- BLS OEWS May 2023 — Los Angeles metro
- CBRE U.S. Life Sciences Talent Trends 2025
- Salary.com — LA vs Houston cost of living
- ProPublica Nonprofit Explorer (Form 990s)
- Texas Tribune Government Salaries Explorer
- Transparent California (UC pay)
- AAMC Faculty Salary Report
It establishes direction and magnitude with verified anchors: LA leads nominal, Houston leads real, and LA owns the industry equity ceiling. For an individual offer, pull the specific employer's data (a hospital's 990, a company's proxy, an MGMA/Medscape specialty cut) and run a real gross-to-net model with that person's actual housing and tax situation.